# CARTITUDE-2 (NCT04133636)

> A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04133636
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: JNJ-68284528; Lenalidomide; Daratumumab; Bortezomib; Dexamethasone
- Enrollment: 208
- Primary outcome: Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
- Primary outcome: For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)

## Commentary we found

- YouTube: 28
- Podcasts: 18
- X threads: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cartitude-2-nct04133636

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04133636", "email": "<work email>"}; the inbox owner confirms by the emailed link.